TY - JOUR T1 - Golimumab for ulcerative colitis: adding perspective to the pursuit JF - Frontline Gastroenterology JO - Frontline Gastroenterol DO - 10.1136/flgastro-2017-100929 SP - flgastro-2017-100929 AU - Jimmy K Limdi Y1 - 2017/11/29 UR - http://fg.bmj.com/content/early/2017/11/29/flgastro-2017-100929.abstract N2 - Anti-TNF therapies have had a transformational effect on our treatment paradigms for ulcerative colitis (UC). Golimumab (GLM) received regulatory approval for the treatment of moderately to severely active UC, following demonstration of efficacy and safety in the induction (PURSUIT-SC) and maintenance (PURSUIT-M) trials.1 2 The trial objective was to obtain regulatory approval, not to inform clinicians on optimising its use in clinical practice. In that sense, the inclusion of anti-TNF naive patients arguably represented ‘low-hanging fruit’. Yet, trials leave a trail that subsequent studies must tread.Adding to our understanding, Samaan and colleagues present a timely ‘real-world’ experience with GLM from two tertiary inflammatory bowel disease (IBD) centres. … ER -